Key facts
- This page summarizes Jay Shepard's Form 4 filing for INOVIO PHARMACEUTICALS, INC. (INO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Jan 2022, 15:06.
Jay Shepard - 15 Jan 2022 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)
- Reporting relationship
- Director
- Issuer ticker
- INO
- Reported as of
- 15 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Jan 2022, 15:06:22 UTC
- Prior SEC filing
- 04 Jun 2021
- Next SEC filing
- 17 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jay P. Shepard
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jay Shepard filed Form 4 for INOVIO PHARMACEUTICALS, INC. (INO) on 18 Jan 2022.
Change
- Previous filing in this sequence was filed on 04 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,274
- Change %
- +33%
- Price
- Shares after
- 17,248
- Date
- 15 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INO
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -4,274
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 4,273
- Date
- 15 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,274
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both